Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company founded in 1988 by Leonard Schleifer and George Yancopoulos. Headquartered in Tarrytown, New York, the company specializes in developing and commercializing medicines for serious diseases. Known for its innovative research and development, Regeneron focuses on areas such as ophthalmology, oncology, immunology, and more. As of 2023, Leonard Schleifer serves as the CEO, continuing to steer the company toward groundbreaking medical advancements. Regeneron achieved significant recognition for its development of treatments such as EYLEA for eye diseases and its COVID-19 antibody cocktail. With a commitment to scientific excellence and patient care, Regeneron has become a respected name in the biotechnology sector, boasting over $12 billion in revenue in recent years.